Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...
After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement.
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...
Telemedicine once seemed like it was going to revolutionize healthcare.
Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...
Private equity giants Vista Equity Partners and Blackstone (BX) are nearing a significant acquisition deal to buy Smartsheet, a collaboration-software company, for around $8 billion. Sources familiar with...
The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.
The September syndrome is already visible in U.S. stock markets. September is known to be the worst-performing month for Wall Street. This year, too, the situation remains challenging. Major stock indexes...